Organogenesis Holdings Inc. Class A Common Stock (ORGO)
Summary
Organogenesis Q2 Earnings Call Highlights
Organogenesis NASDAQ: ORGO reported a sharp year-over-year decline in second-quarter revenue as the skin substitute market continued to adjust to coverage and payment changes from the Centers for Medicare & Medicaid Services, while management pointed to sequential improvement in product sales and market share gains.
Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript
Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript
Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked
Organogenesis is grappling with significant revenue declines in 2026 due to adverse Medicare policy changes impacting its core skin substitute products. 2025 marked a peak year for ORGO, but 2026 guidance now calls for a 45–52% year-over-year revenue drop to $270–310 million. Market headwinds have intensified, with clinicians in some cases moving away from skin substitutes entirely, compounding ORGO's challenges.
Organogenesis Holdings Inc. Class A Common Stock Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 855 | $2,156.26 | $825.07 | -$1,331.19 | -61.74% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 6,521 | $29,361.84 | $6,288.85 | -$23,072.99 | -78.58% |
| BG Bart Gancher Intech Investment Management LLC | 16,099 | $63,526.56 | $16,099 | -$47,427.56 | -74.66% |
| AW Anne-Lise Wiegand SENTINEL TRUST Co. LBA | 37,259 | $283,913.58 | $49,927.06 | -$233,986.52 | -82.41% |
| MM Mike Muhizi SG Americas Securities LLC | 772,737 | $3.22M | $726,527.33 | -$2.5M | -77.46% |
Organogenesis Holdings Inc. Class A Common Stock (ORGO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Organogenesis Holdings Inc. Class A Common Stock ever had a stock split?
Organogenesis Holdings Inc. Class A Common Stock Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Gary S. Gillheeney CEO | NASDAQ (CM) Exchange | 68621F102 CUSIP |
| US Country | 854 Employees | - Last Dividend | - Last Split | 5 Jan 2017 IPO Date |
Overview
Organogenesis Holdings Inc. is a pioneering regenerative medicine company dedicated to developing, manufacturing, and commercializing innovative solutions primarily for the advanced wound care, and surgical and sports medicine markets within the United States. With its foundation dating back to 1985, Organogenesis Holdings Inc. has established its headquarters in Canton, Massachusetts. The company is renowned for its commitment to enhancing patient care by providing cutting-edge regenerative medicine products and therapies. Through its direct sales representatives and independent agencies, Organogenesis serves a diverse clientele, including hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices.
Products and Services
Affinity: An amniotic membrane product preserving viable cells, growth factors/cytokines, and extracellular matrix (ECM) proteins from the native tissue, offering advanced wound care solutions.
Novachor: Similar to Affinity, Novachor is a chorion membrane product that retains viable cells, growth factors/cytokines, and ECM proteins, aimed at enhancing wound healing processes.
Apligraf: A pioneering bioengineered living cell therapy that produces a broad spectrum of cytokines and growth factors, designed for the treatment of wounds.
Dermagraft: A bioengineered product known for producing human collagen, ECM proteins, cytokines, and growth factors, contributing to effective wound repair.
NuShield: A dehydrated placental tissue product covering both amnion and chorion membranes to keep the spongy/intermediate layer intact, designed for wound care management.
PuraPly AM: This antimicrobial barrier is known for its conformability and fluid drainage capabilities, offering a solution in the management of wound infections.
FortiShield: A biosynthetic wound matrix developed for use as a temporary protective covering for wounds, part of the advanced wound care line-up.
PuraPly MZ: A micronized particulate version of PuraPly, designed specifically for the management of open wounds in a surgical setting.
CYGNUS Dual: A dehydrated placental tissue product, preserved meticulously to retain the ECM scaffold, offering support in wound care.
ReNu: A pipeline product, ReNu is a cryopreserved suspension aimed to support the healing of soft tissues, showcasing the company's ongoing innovation.
PuraForce: Another bioengineered product in the pipeline, PuraForce is a porcine collagen surgical matrix intended for soft tissue reinforcement applications.
TransCyte: A bioengineered tissue designed for the treatment of partial thickness burns, reflecting the company's commitment to addressing a broad range of medical challenges.
Contact Information
